{"id":"dicl-sr","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset (dyspepsia, abdominal pain)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Increased risk of cardiovascular events (with long-term use)"},{"rate":null,"effect":"Increased risk of gastrointestinal bleeding"}]},"_chembl":{"chemblId":"CHEMBL2075003","moleculeType":"Small molecule","molecularWeight":"258.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2 enzymes, thereby decreasing prostaglandin production. The SR (sustained-release) formulation extends the drug's duration of action, allowing for less frequent dosing while maintaining therapeutic levels. This mechanism reduces inflammation, pain, and fever across various musculoskeletal and inflammatory conditions.","oneSentence":"DICL-SR is a sustained-release formulation of diclofenac that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide anti-inflammatory, analgesic, and antipyretic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:45.708Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"},{"name":"Acute pain and inflammation"}]},"trialDetails":[{"nctId":"NCT02826031","phase":"PHASE4","title":"Clinical Study of Artz in the Treatment of Knee Osteoarthritis","status":"UNKNOWN","sponsor":"Kunming Baker Norton Pharmaceutical Sales Co., Ltd.","startDate":"2016-04","conditions":"Knee Osteoarthritis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DICL-SR","genericName":"DICL-SR","companyName":"Kunming Baker Norton Pharmaceutical Sales Co., Ltd.","companyId":"kunming-baker-norton-pharmaceutical-sales-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DICL-SR is a sustained-release formulation of diclofenac that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and provide anti-inflammatory, analgesic, and antipyretic effects. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}